<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420652</url>
  </required_header>
  <id_info>
    <org_study_id>081501</org_study_id>
    <secondary_id>NCI-2015-00397</secondary_id>
    <secondary_id>081501</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT02420652</nct_id>
  </id_info>
  <brief_title>Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy</brief_title>
  <acronym>PRIMA</acronym>
  <official_title>A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers Cancer Institute of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well metformin hydrochloride and aspirin work in&#xD;
      treating patients with hormone-dependent prostate cancer that has progressed after surgery or&#xD;
      radiation therapy. Metformin hydrochloride and aspirin may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. It is not yet known whether giving&#xD;
      metformin hydrochloride and aspirin together can slow the growth of prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effect of metformin (metformin hydrochloride) and aspirin on the change&#xD;
      in prostate-specific antigen (PSA) progression in men with rising PSA after definitive&#xD;
      therapy for localized prostate cancer and stable disease during a run-in period with the&#xD;
      study regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility and safety of administering metformin and aspirin.&#xD;
&#xD;
      II. To determine the effect of metformin and aspirin on PSA levels and the serum&#xD;
      obesity-related prostate cancer (PCa) biomarkers (insulin, insulin-like growth factor&#xD;
      [IGF]-1, interleukin [IL]-1beta, IL-6, and tumor necrosis factor [TNF]-alpha).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      RUN-IN STAGE: Patients receive metformin hydrochloride orally (PO) twice daily (BID) and&#xD;
      aspirin PO once daily (QD) for 4 months. Patients with disease progression (PSA increase of &gt;&#xD;
      50% and minimum of 2ng/ml rise in PSA) come off study. Patients achieving disease response&#xD;
      (&gt;25% decline in PSA) continue to receive study agents in the absence of disease progression&#xD;
      or unacceptable disease. Patients with stable disease continue on to the randomized study&#xD;
      regimen.&#xD;
&#xD;
      RANDOMIZATION STAGE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for&#xD;
      6 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 12-16 weeks for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 23, 2015</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stable PSA rates after 6 months of metformin hydrochloride and aspirin or placebo therapy in patients who have received 4 months of open label treatment</measure>
    <time_frame>Baseline to up to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (metformin hydrochloride, aspirin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (metformin hydrochloride placebo, aspirin placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (metformin hydrochloride, aspirin)</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
    <other_name>ASA</other_name>
    <other_name>Aspergum</other_name>
    <other_name>Ecotrin</other_name>
    <other_name>Empirin</other_name>
    <other_name>Entericin</other_name>
    <other_name>Extren</other_name>
    <other_name>Measurin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (metformin hydrochloride, aspirin)</arm_group_label>
    <arm_group_label>Arm II (metformin hydrochloride placebo, aspirin placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (metformin hydrochloride, aspirin)</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Metformin HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given metformin hydrochloride placebo PO</description>
    <arm_group_label>Arm II (metformin hydrochloride placebo, aspirin placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given aspirin placebo PO</description>
    <arm_group_label>Arm II (metformin hydrochloride placebo, aspirin placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven prostate cancer treated with surgery, radiation,&#xD;
             or the combination of surgery and radiation for prostate cancer (metastatic to&#xD;
             regional lymph nodes) with resection of the nodes, who now has a rising PSA value&#xD;
             after definitive local therapy, and no visible metastatic disease on conventional&#xD;
             imaging studies&#xD;
&#xD;
          -  Patients must have undergone local treatment via prostatectomy or radiation therapy&#xD;
&#xD;
          -  Patients must have PSA progression after local treatment:&#xD;
&#xD;
               -  PSA values for patients after surgery (or surgery and salvage/adjuvant radiation)&#xD;
                  must be greater than or equal to 0.2 ng/mL, determined by two measurements, at&#xD;
                  least 1 month apart and at least 6 months after prostatectomy&#xD;
&#xD;
               -  PSA values for patients after radiation must be greater than or equal to 2.0&#xD;
                  ng/ml greater than the nadir achieved after radiation, determined by two&#xD;
                  measurements at 1 month apart and at least 6 months after the radiation treatment&#xD;
                  is completed; (patients who received adjuvant or salvage radiation after&#xD;
                  prostatectomy must have PSA of greater than or equal to 0.2)&#xD;
&#xD;
               -  The first two PSA values, along with a third (study baseline) value must all be&#xD;
                  rising (i.e., there must be an overall rising trajectory, such that the third&#xD;
                  value cannot be lower than the first value)&#xD;
&#xD;
               -  PSA must be less than 50 ng/mL at study entry&#xD;
&#xD;
               -  PSA doubling time using the mkscc.org PSA doubling time calculator must be&#xD;
                  greater than 4 months&#xD;
&#xD;
          -  Baseline bone scan, chest x-ray and computed tomography (CT)/magnetic resonance&#xD;
             imaging (MRI) of abdomen/pelvis demonstrating no metastatic disease&#xD;
&#xD;
          -  Estimated life expectancy of at least 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  White blood cells (WBC) &gt; 3500/ul&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1500/ul&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dl&#xD;
&#xD;
          -  Platelet count &gt; 100,000/ul&#xD;
&#xD;
          -  Adequate renal function with estimated glomerular filtration rate (GFR) by Cockcroft&#xD;
             Gault of greater than 40 ML per minute&#xD;
&#xD;
          -  Total bilirubin must be within 1.5 X the normal institutional limits; if total&#xD;
             bilirubin is outside the normal institutional limits, assess direct bilirubin&#xD;
&#xD;
          -  The direct bilirubin must be within normal parameters&#xD;
&#xD;
          -  Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamate&#xD;
             pyruvate transaminase [SGPT]) must be less than 2.5 X the institutional upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Patients must have a serum total testosterone level &gt;= 150 ng/dL at the time of&#xD;
             enrollment within 4 weeks prior to randomization&#xD;
&#xD;
          -  Patients must sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious concomitant systemic disorder that would compromise the safety of the patient&#xD;
             or compromise the patient's ability to complete the study, at the discretion of the&#xD;
             investigator&#xD;
&#xD;
          -  Patients may have received prior androgen deprivation therapy (ADT) in the&#xD;
             neoadjuvant, adjuvant and/or salvage setting, but must be off therapy for at least 3&#xD;
             months and have a testosterone level &gt; 150 ng/dl&#xD;
&#xD;
          -  Second primary malignancy except most situ carcinoma (e.g. adequately treated&#xD;
             non-melanomatous carcinoma of the skin) or other malignancy treated at least 2 years&#xD;
             previously with no evidence of recurrence&#xD;
&#xD;
          -  Patients with type II diabetes currently already on metformin&#xD;
&#xD;
          -  Patients taking aspirin for previously diagnosed cardiovascular disease&#xD;
&#xD;
          -  Patients who received aspirin or metformin within the past 28 days&#xD;
&#xD;
          -  Patients taking medications with known interactions with metformin or aspirin&#xD;
&#xD;
          -  Patients taking warfarin or platelet inhibitors&#xD;
&#xD;
          -  Patients requiring chronic use of nonsteroidal anti-inflammatory drugs (NSAIDS)&#xD;
&#xD;
          -  Other concurrent experimental or investigational drugs&#xD;
&#xD;
          -  Prior history of lactic acidosis or metabolic acidosis&#xD;
&#xD;
          -  Patients with history of gastrointestinal (GI) bleeding and peptic ulcer disease&#xD;
&#xD;
          -  Any unstable, serious co-existing medical conditions including but not limited to&#xD;
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,&#xD;
             clinically evident congestive heart failure, or cerebrovascular accident within 6&#xD;
             months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biren Saraiya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers Cancer Institute of New Jersey</investigator_affiliation>
    <investigator_full_name>Biren Saraiya, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

